GSK's RSV jab, Arexvy will now compete for market share with Pfizer’s Abrysvo and Moderna’s mRESVIA across the high-risk ...

GRANTS PASS, OR / ACCESS Newswire / March 16, 2026 / Venture capitalist and biotech entrepreneur Andrew Hamilton, through his investment firm Pale Horse Capital, has acquired the premium ...

Pakistani student Muhammad Jalal (right) works in a laboratory at Anhui Agricultural University in Hefei, Anhui province, on March 9. [Photo/Xinhua] HEFEI — Almost every morning, Muhammad Jalal finds ...

GRANTS PASS, OR / ACCESS Newswire / March 16, 2026 / Venture capitalist and biotech entrepreneur Andrew Hamilton, through his ...

London biotech startup Ternary Therapeutics has raised £3.6m to scale its AI-powered platform designed to engineer molecular ...

US$959.5 million, +61.4% year-on-yearGross profit: US$553.2 million, +103.3% year-on-yearAdjusted net profit: US$230.3 million, +285.0% year-on-yearBusiness Units' PerformanceGenScript Life Science ...

Demand for home-based medical technologies is expected to grow significantly over the next decade. ... Read More The post Ageing Asia fuels demand for wearable therapies as Australian device enters ...

Turning the Page Radio 3/BBC Sounds, 1pm Violinist Tasmin Little’s elegiac series, looking at how, when and why classical ...

The push to revive extinct animals is accelerating, but scientists disagree about whether gene-edited species count as true "de-extinction." ...

Cosentyx’s IL-17A mechanism provides a differentiated approach for HS in younger patients.

A biotech company which aims to revolutionise drug testing using lab-grown human muscles has secured the backing of a seed-stage investor to accelerate its growth.

The company’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise and a pipeline focused on cancer treatments.